Braxia Scientific Corp.

Braxia Scientific Corp. (OTC: BRAXF) is a Canadian medical research and telemedicine company headquartered in Mississauga, Ontario, that operated multidisciplinary clinics providing innovative ketamine treatments for individuals suffering from depression and related mental health disorders. The company was also engaged in discovering and commercializing novel drugs and delivery methods, developing derivatives of ketamine and psilocybin, and other psychedelic products through its proprietary IP development platform. However, following a failure-to-file cease trade order issued by the Ontario Securities Commission in August 2024 and a subsequent asset sale, Braxia Scientific disclosed minimal cash assets and a significant working capital deficiency, with the company now in the process of winding down operations. Trading on the OTC Pink marketplace under the symbol BRAXF, the stock has seen its market capitalization decline sharply, reflecting the company's deteriorating financial position and cessation of active business pursuits.